医学
中性粒细胞减少症
发热性中性粒细胞减少症
化疗
重症监护医学
内科学
药物治疗
药理学
肿瘤科
出处
期刊:Drugs
[Springer Nature]
日期:2023-06-27
卷期号:83 (12): 1125-1130
被引量:2
标识
DOI:10.1007/s40265-023-01911-7
摘要
Efbemalenograstim alfa (Ryzneuta®) is a subcutaneously administered recombinant fusion protein that is being developed by Evive Biotech for the management of chemotherapy-induced neutropenia. On 6 May 2023, efbemalenograstim alfa was approved in China for reducing the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignant tumours who are treated with myelosuppressive anticancer drugs that are prone to cause febrile neutropenia. Efbemalenograstim alfa is under regulatory review for the management of chemotherapy-induced neutropenia in the EU and the USA. This article summarizes the milestones in the development of efbemalenograstim alfa leading to this first approval for the management of chemotherapy-induced neutropenia.
科研通智能强力驱动
Strongly Powered by AbleSci AI